{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:12:55Z","timestamp":1767845575705,"version":"3.49.0"},"reference-count":59,"publisher":"Elsevier","isbn-type":[{"value":"9780128093856","type":"print"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1016\/bs.pmbts.2016.05.004","type":"book-chapter","created":{"date-parts":[[2016,7,10]],"date-time":"2016-07-10T01:47:33Z","timestamp":1468115253000},"page":"291-315","source":"Crossref","is-referenced-by-count":2,"title":["Translational Activities to Enable NTD Vaccines"],"prefix":"10.1016","author":[{"given":"S.A.","family":"Gray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.N.","family":"Coler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/bs.pmbts.2016.05.004_bib0300","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1017\/S0022149X15000206","article-title":"The human hookworm vaccine: recent updates and prospects for success","volume":"89","author":"Bottazzi","year":"2015","journal-title":"J Helminthol"},{"key":"10.1016\/bs.pmbts.2016.05.004_bib0305","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev-med-051214-024241","article-title":"New vaccines for the world's poorest people","volume":"67","author":"Hotez","year":"2015","journal-title":"Annu Rev Med"},{"issue":"Suppl 2","key":"10.1016\/bs.pmbts.2016.05.004_bib0310","doi-asserted-by":"crossref","first-page":"B227","DOI":"10.1016\/j.vaccine.2012.11.034","article-title":"The human hookworm vaccine","volume":"31","author":"Hotez","year":"2013","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/bs.pmbts.2016.05.004_bib0315","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.4161\/hv.28872","article-title":"Optimization and revision of the production process of the Necator americanus glutathione S-transferase 1 (Na-GST-1), the lead hookworm vaccine recombinant protein candidate","volume":"10","author":"Curti","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"39","key":"10.1016\/bs.pmbts.2016.05.004_bib0320","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1016\/j.vaccine.2005.04.040","article-title":"Expression of the Necator americanus hookworm larval antigen Na-ASP-2 in Pichia pastoris and purification of the recombinant protein for use in human clinical trials","volume":"23","author":"Goud","year":"2005","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/bs.pmbts.2016.05.004_bib0325","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1080\/21645515.2015.1036207","article-title":"Expression, purification, and characterization of the Necator americanus aspartic protease-1 (Na-APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine","volume":"11","author":"Seid","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/bs.pmbts.2016.05.004_bib0330","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1586\/14760584.2014.872035","article-title":"Advancing a multivalent \u2018Pan-anthelmintic\u2019 vaccine against soil-transmitted nematode infections","volume":"13","author":"Zhan","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"10.1016\/bs.pmbts.2016.05.004_bib0335","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1586\/14760584.2016.1131127","article-title":"Development of a schistosomiasis vaccine","volume":"15","author":"Molehin","year":"2016","journal-title":"Expert Rev Vaccines"},{"issue":"11","key":"10.1016\/bs.pmbts.2016.05.004_bib0340","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.vaccine.2013.12.057","article-title":"Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons","volume":"32","author":"Karmakar","year":"2014","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/bs.pmbts.2016.05.004_bib0345","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1093\/infdis\/jiu031","article-title":"Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons","volume":"209","author":"Karmakar","year":"2014","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/bs.pmbts.2016.05.004_bib0350","doi-asserted-by":"crossref","first-page":"e2865","DOI":"10.1371\/journal.pntd.0002865","article-title":"The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases","volume":"8","author":"Hotez","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/bs.pmbts.2016.05.004_bib0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2015.03.017","article-title":"Vaccines for visceral leishmaniasis: a review","volume":"422","author":"Jain","year":"2015","journal-title":"J Immunol Methods"},{"issue":"3","key":"10.1016\/bs.pmbts.2016.05.004_bib0360","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.vaccine.2012.11.032","article-title":"The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas","volume":"31","author":"Bacon","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/bs.pmbts.2016.05.004_bib0365","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.vaccine.2011.11.005","article-title":"The development and clinical evaluation of second-generation leishmaniasis vaccines","volume":"30","author":"Duthie","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/bs.pmbts.2016.05.004_bib0370","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"Coler","year":"2015","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/bs.pmbts.2016.05.004_bib0375","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1186\/s13071-014-0466-x","article-title":"The global distribution and transmission limits of lymphatic filariasis: past and present","volume":"7","author":"Cano","year":"2014","journal-title":"Parasit Vectors"},{"issue":"9","key":"10.1016\/bs.pmbts.2016.05.004_bib0380","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ijpara.2014.04.006","article-title":"Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model","volume":"44","author":"Hess","year":"2014","journal-title":"Int J Parasitol"},{"issue":"1","key":"10.1016\/bs.pmbts.2016.05.004_bib0385","doi-asserted-by":"crossref","first-page":"e0003422","DOI":"10.1371\/journal.pntd.0003422","article-title":"The Onchocerciasis Vaccine for Africa\u2014TOVA\u2014Initiative","volume":"9","author":"Hotez","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/bs.pmbts.2016.05.004_bib0390","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/1756-3305-7-307","article-title":"Innovative tools for assessing risks for severe adverse events in areas of overlapping Loa loa and other filarial distributions: the application of micro-stratification mapping","volume":"7","author":"Kelly-Hope","year":"2014","journal-title":"Parasit Vectors"},{"issue":"10","key":"10.1016\/bs.pmbts.2016.05.004_bib0395","doi-asserted-by":"crossref","first-page":"e2300","DOI":"10.1371\/journal.pntd.0002300","article-title":"An unfolding tragedy of Chagas disease in North America","volume":"7","author":"Hotez","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"10.1016\/bs.pmbts.2016.05.004_bib0400","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1371\/journal.pntd.0000484","article-title":"New, improved treatments for Chagas disease: from the R&D pipeline to the patients","volume":"3","author":"Ribeiro","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"issue":"9","key":"10.1016\/bs.pmbts.2016.05.004_bib0405","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1586\/erv.12.85","article-title":"Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects","volume":"11","author":"Dumonteil","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/bs.pmbts.2016.05.004_bib0410","first-page":"315","article-title":"Cysticercosis and echinococcosis","volume":"365","author":"Lightowlers","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"10.1016\/bs.pmbts.2016.05.004_bib0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actatropica.2012.02.066","article-title":"Challenges for diagnosis and control of cystic hydatid disease","volume":"123","author":"Barnes","year":"2012","journal-title":"Acta Trop"},{"issue":"7446","key":"10.1016\/bs.pmbts.2016.05.004_bib0420","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"issue":"3","key":"10.1016\/bs.pmbts.2016.05.004_bib0425","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.trsl.2013.03.006","article-title":"New vaccines for neglected parasitic diseases and dengue","volume":"162","author":"Beaumier","year":"2013","journal-title":"Transl Res"},{"key":"10.1016\/bs.pmbts.2016.05.004_bib0430","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcv.2014.08.032","article-title":"Chikungunya, a paradigm of neglected tropical disease that emerged to be a new health global risk","volume":"64","author":"Rougeron","year":"2015","journal-title":"J Clin Virol"},{"key":"10.1016\/bs.pmbts.2016.05.004_bib0435","doi-asserted-by":"crossref","first-page":"834371","DOI":"10.1155\/2015\/834371","article-title":"Diagnostic options and challenges for dengue and chikungunya viruses","volume":"2015","author":"Mardekian","year":"2015","journal-title":"Biomed Res Int"},{"issue":"31","key":"10.1016\/bs.pmbts.2016.05.004_bib0440","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1016\/j.vaccine.2015.05.104","article-title":"Chikungunya virus vaccines: current strategies and prospects for developing plant-made vaccines","volume":"33","author":"Salazar-Gonzalez","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/bs.pmbts.2016.05.004_bib0445","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijpddr.2014.02.002","article-title":"Drug repurposing and human parasitic protozoan diseases","volume":"4","author":"Andrews","year":"2014","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"6","key":"10.1016\/bs.pmbts.2016.05.004_bib0450","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nrd4001-c1","article-title":"Drug discovery for the developing world: progress at the Novartis Institute for Tropical Diseases","volume":"14","author":"Jones","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/bs.pmbts.2016.05.004_bib0455","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nrd2144","article-title":"Innovative lead discovery strategies for tropical diseases","volume":"5","author":"Nwaka","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/bs.pmbts.2016.05.004_bib0460","doi-asserted-by":"crossref","first-page":"e3092","DOI":"10.1371\/journal.pntd.0003092","article-title":"Current pipelines for neglected diseases","volume":"8","author":"di Procolo","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"10.1016\/bs.pmbts.2016.05.004_bib0465","doi-asserted-by":"crossref","first-page":"e1803","DOI":"10.1371\/journal.pntd.0001803","article-title":"Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade","volume":"6","author":"Stefanakis","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/bs.pmbts.2016.05.004_bib0470","unstructured":"FDA, U.F.a.D.A. FDA draft guidance for industry: tropical disease priority review vouchers, FDA. Washington DC, Government Printing Office; 2008."},{"issue":"8","key":"10.1016\/bs.pmbts.2016.05.004_bib0475","doi-asserted-by":"crossref","first-page":"e1750","DOI":"10.1371\/journal.pntd.0001750","article-title":"The impact of the US priority review voucher on private-sector investment in global health research and development","volume":"6","author":"Robertson","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"9","key":"10.1016\/bs.pmbts.2016.05.004_bib0480","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.4161\/hv.20966","article-title":"Modeling the economic value of a Chagas\u2019 disease therapeutic vaccine","volume":"8","author":"Lee","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/bs.pmbts.2016.05.004_bib0485","first-page":"68","article-title":"A stability program for the distribution of drug product","volume":"July","author":"Lucas","year":"2004","journal-title":"Pharm Technol"},{"issue":"2","key":"10.1016\/bs.pmbts.2016.05.004_bib0490","first-page":"1","article-title":"Regulatory strategy for long-term stability conditions to support submission in zone IV countries","volume":"12","author":"Seevers","year":"2011","journal-title":"Pharm Outsourcing"},{"issue":"4","key":"10.1016\/bs.pmbts.2016.05.004_bib0495","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(14)70033-5","article-title":"Progress in tuberculosis vaccine development and host-directed therapies\u2014a state of the art review","volume":"2","author":"Kaufmann","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/bs.pmbts.2016.05.004_bib0500","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1517\/17460441.2014.941801","article-title":"Latest approaches for efficient protein production in drug discovery","volume":"9","author":"Sugiki","year":"2014","journal-title":"Expert Opin Drug Discov"},{"issue":"3","key":"10.1016\/bs.pmbts.2016.05.004_bib0505","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/21645515.2015.1101197","article-title":"Chikungunya vaccines in development","volume":"12","author":"Schwameis","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/bs.pmbts.2016.05.004_bib0510","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/1097-0290(20001120)70:4<381::AID-BIT3>3.0.CO;2-0","article-title":"Studies related to the scale-up of high-cell-density E. coli fed-batch fermentations using multiparameter flow cytometry: effect of a changing microenvironment with respect to glucose and dissolved oxygen concentration","volume":"70","author":"Hewitt","year":"2000","journal-title":"Biotechnol Bioeng"},{"issue":"1","key":"10.1016\/bs.pmbts.2016.05.004_bib0515","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0734-9750(98)00015-9","article-title":"Control of fed-batch fermentations","volume":"17","author":"Lee","year":"1999","journal-title":"Biotechnol Adv"},{"key":"10.1016\/bs.pmbts.2016.05.004_bib0520","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2859-5-17","article-title":"Operational strategies, monitoring and control of heterologous protein production in the methylotrophic yeast Pichia pastoris under different promoters: a review","volume":"5","author":"Cos","year":"2006","journal-title":"Microb Cell Fact"},{"key":"10.1016\/bs.pmbts.2016.05.004_bib0525","unstructured":"M. Ngibuini, How single-use, mini bioreactors could revolutionize bioprocess scale-up. Available from: http:\/\/www.bioprocessintl.com\/upstream-processing\/bioreactors\/automated-mini-bioreactor-technology-microbial-mammalian-cell-culture-flexible-strategy-optimize-early-process-development-biologics-vaccines-2\/"},{"issue":"6","key":"10.1016\/bs.pmbts.2016.05.004_bib0530","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/biot.201300236","article-title":"Challenges in industrial fermentation technology research","volume":"9","author":"Formenti","year":"2014","journal-title":"Biotechnol J"},{"key":"10.1016\/bs.pmbts.2016.05.004_bib0535","unstructured":"Jones SD, Kanarek A, Levine H. Reliable scale-up for biopharmaceutical production. BioProcess Technology Consultants, 2012; Available from: http:\/\/www.chem.info\/article\/2012\/10\/reliable-scale-biopharmaceutical-production."},{"issue":"1","key":"10.1016\/bs.pmbts.2016.05.004_bib0540","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1186\/s12936-015-0972-0","article-title":"Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants","volume":"14","author":"Roeffen","year":"2015","journal-title":"Malar J"},{"issue":"6","key":"10.1016\/bs.pmbts.2016.05.004_bib0545","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1128\/CVI.00179-14","article-title":"Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24","volume":"21","author":"Gupta","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/bs.pmbts.2016.05.004_bib0550","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2013.07.030","article-title":"Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis","volume":"172","author":"Orr","year":"2013","journal-title":"J Control Release"},{"issue":"10","key":"10.1016\/bs.pmbts.2016.05.004_bib0555","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/bs.pmbts.2016.05.004_bib0560","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems","volume":"10","author":"Garcon","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"10","key":"10.1016\/bs.pmbts.2016.05.004_bib0565","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nbt1015-1015","article-title":"Landmark green light for Mosquirix malaria vaccine","volume":"33","author":"Morrison","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/bs.pmbts.2016.05.004_bib0570","doi-asserted-by":"crossref","first-page":"e84707","DOI":"10.1371\/journal.pone.0084707","article-title":"Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen","volume":"9","author":"McKay","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/bs.pmbts.2016.05.004_bib0575","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1128\/IAI.02980-14","article-title":"Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes","volume":"83","author":"Patra","year":"2015","journal-title":"Infect Immun,"},{"issue":"93","key":"10.1016\/bs.pmbts.2016.05.004_bib0580","doi-asserted-by":"crossref","first-page":"93ra69","DOI":"10.1126\/scitranslmed.3002135","article-title":"Targeting TLRs expands the antibody repertoire in response to a malaria vaccine","volume":"3","author":"Wiley","year":"2011","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/bs.pmbts.2016.05.004_bib0585","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/eji.201444543","article-title":"Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-gamma","volume":"45","author":"Desbien","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1016\/bs.pmbts.2016.05.004_bib0590","series-title":"WHO Guidelines on the nonclinical evaluation adjuvants and adjuvanted vaccines","year":"2013"}],"container-title":["Progress in Molecular Biology and Translational Science","Host-Microbe Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117316300084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117316300084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T16:26:27Z","timestamp":1536596787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117316300084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9780128093856"],"references-count":59,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2016.05.004","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}